Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.38 |
| ▸ | DRD3 | P35462 | 8/20 | 0.38 |
| ▸ | DRD4 | P21917 | 6/20 | 0.38 |
| ▸ | DRD1 | P21728 | 5/20 | 0.38 |
| ▸ | DRD5 | P21918 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 2/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13132636 | 0.90 | DRD2 (0.47) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL13560702 | 0.88 | DRD2 (0.40) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL31342579 | 0.88 | DRD2 (0.40) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL3678529 | 0.85 | DRD2 (0.37) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL24923816 | 0.85 | DRD2 (0.39) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL17459560 | 0.82 | DRD2 (0.44) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL16787830 | 0.81 | DRD2 (0.38) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL31342610 | 0.80 | DRD2 (0.35) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL602165 | 0.79 | STS (0.40) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL13132554 | 0.79 | DRD2 (0.33) | DRD2DRD3DRD4DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10959986-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200069646-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL MYERS SQUIBB CO (US) | 2020-03-05 | — | — | US | disclosed |
| US-9321736-B2 | Pyrimidine cyclohexyl glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| EP-2685827-B1 | PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INC (US) | 2016-02-03 | — | — | EP | disclosed |
| US-20150065532-A1 | PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. | 2015-03-05 | — | — | US | disclosed |
| EP-2109611-B1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MAN CO LTD (JP) | 2015-01-07 | — | — | EP | disclosed |
| US-8906917-B2 | Pyrimidine cyclohexyl glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140162361-A1 | PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. | 2014-06-12 | — | — | US | disclosed |
| EP-2685827-A1 | PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics, Inc. (US) | 2014-01-22 | — | — | EP | disclosed |
| US-20130072486-A1 | PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2109611-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | Eisai R&D Management Co., Ltd. (JP) | 2009-10-21 | — | — | EP | disclosed |
| WO-2008095944-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
| EP-1534700-A1 | NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | WARNER-LAMBERT COMPANY LLC | 2004-04-15 | — | — | US | disclosed |
| WO-2004018448-A1 | NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
| EP-1394159-A1 | New thiophene derivatives, process for their preparation and pharmaceutical compositions containing them | Warner-Lambert Company LLC (US) | 2004-03-03 | — | — | EP | disclosed |
| US-5932743-A | Methods for the solid phase synthesis of substituted indole compounds | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-08-03 | — | — | US | disclosed |
| WO-1999009007-A1 | SOLID PHASE SYNTHESIS OF 2,3-DISUBSTITUTED INDOLE COMPOUNDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140162361-A1 | PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, MC2R | DRD2 1899/4885DRD3 1736/4885DRD4 1687/4885 |
| US-10959986-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | DRD2 3235/4885DRD3 3565/4885DRD4 3666/4885 |
| US-20130072486-A1 | PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, MC2R | DRD2 1899/4885DRD3 1736/4885DRD4 1687/4885 |
| US-20150065532-A1 | PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, MC2R | DRD2 1899/4885DRD3 1736/4885DRD4 1687/4885 |
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | MMP11, MMP13, CBR1 | DRD2 3048/4885DRD3 2667/4885DRD4 1917/4885 |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPK13, MAPKAPK5 | DRD2 2626/4885DRD3 2523/4885DRD4 2567/4885 |
| US-20200069646-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | DRD2 3235/4885DRD3 3565/4885DRD4 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.